Ornithine Aketoglutarate

Ornithine Aketoglutarate

SCHEMBL6512486

C=CC(N)=O.C=CC(N)=O.NCCCC(N)C(=O)O.[NaH]

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.62
NOS2 P35228 6/20 0.46
CYP2C19 P33261 2/20 0.46
CYP1A2 P05177 2/20 0.46
TSHR P16473 2/20 0.46
GLA P06280 1/20 0.46
NFKB1 P19838 1/20 0.46
APEX1 P27695 1/20 0.46
KMT2A Q03164 2/20 0.44
ALOX15 P16050 1/20 0.44
BLM P54132 1/20 0.44
PMP22 Q01453 1/20 0.44
NOS1 P29475 5/20 0.43
NOS3 P29474 4/20 0.43
DDAH1 O94760 3/20 0.43
MEN1 O00255 1/20 0.43
ARG2 P78540 4/20 0.43
ARG1 P05089 3/20 0.43
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ornithine Aketoglutarate SCHEMBL2178954 0.98 GSR (0.64) GSRNOS2CYP2C19CYP1A2TSHR
Lysine SCHEMBL6561904 0.93 GSR (0.74) GSRNOS2CYP2C19CYP1A2TSHR
Lysine SCHEMBL27645682 0.93 GSR (0.74) GSRNOS2CYP2C19CYP1A2TSHR
Ornithine Aketoglutarate SCHEMBL6883619 0.92 GSR (0.53) GSRNOS2CYP2C19CYP1A2TSHR
Lysine SCHEMBL28112654 0.91 GSR (0.71) GSRNOS2CYP2C19CYP1A2TSHR
Lysine SCHEMBL28112652 0.91 GSR (0.71) GSRNOS2CYP2C19CYP1A2TSHR
Ornithine Aketoglutarate SCHEMBL10406134 0.86 GSR (0.82) GSRNOS2CYP2C19CYP1A2TSHR
D-Ornithine SCHEMBL10406136 0.86 GSR (0.82) GSRNOS2CYP2C19CYP1A2TSHR
Ornithine SCHEMBL15904598 0.84 GSR (0.78) GSRNOS2CYP2C19CYP1A2TSHR
Ornithine SCHEMBL3952790 0.84 GSR (0.78) GSRNOS2CYP2C19CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050129769-A1 Polymeric articles for carrying therapeutic agents ALNIS BIOSCIENCES, INC. 2005-06-16 US disclosed
EP-1531868-A2 THERAPEUTIC AGENT-CONTAINING POLYMERIC NANOARTICLES Alnis Biosciences, Inc. (US) 2005-05-25 EP disclosed
WO-2005027873-A2 THERAPEUTIC AMINOGLYCOSIDE-CONTAINING HYDROGEL NANOPARTICLES ALNIS BIOSCIENCES, INC. (US) 2005-03-31 WO disclosed
US-20040126900-A1 High affinity peptide- containing nanoparticles ALNIS BIOSCIENCES INC. 2004-07-01 US disclosed
US-20040058006-A1 High affinity nanoparticles ALNIS BIOSCIENCES, INC. 2004-03-25 US disclosed
WO-2003101425-A2 THERAPEUTIC AGENT-CONTAINING POLYMERIC NANOARTICLES ALNIS BIOSCIENCES, INC. (US) 2003-12-11 WO disclosed
US-6217901-B1 POLYMERIZING POLYMER AND LIPOSOMES ALNIS, LLC 2001-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050129769-A1 Polymeric articles for carrying therapeutic agents CD44, EPCAM, CLTB GSR 1597/4885NOS2 2399/4885CYP2C19 4881/4885
US-20040126900-A1 High affinity peptide- containing nanoparticles LNPEP, IAPP, ACP1 GSR 4378/4885NOS2 2434/4885CYP2C19 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.